carbostyril has been researched along with Thrombocythemia, Essential in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gray, LA; Kaufmann, SH; Mesa, RA; Reeder, T; Schroeder, G; Tefferi, A | 1 |
| Camoriano, JK; Erlichman, C; Finke, C; Geyer, SM; Kaufmann, SH; Lasho, T; Li, CY; Mesa, RA; Pardanani, A; Rivera, CE; Tefferi, A; Wright, J; Wu, W | 1 |
1 trial(s) available for carbostyril and Thrombocythemia, Essential
| Article | Year |
|---|---|
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bone Marrow; Female; Humans; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinolones; Thrombocythemia, Essential; Treatment Outcome | 2007 |
1 other study(ies) available for carbostyril and Thrombocythemia, Essential
| Article | Year |
|---|---|
In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Survival; Cells, Cultured; Chromones; Colony-Forming Units Assay; Enzyme Inhibitors; Erythrocyte Count; Farnesyltranstransferase; Female; Flavonoids; GPI-Linked Proteins; Hematopoietic Stem Cells; Humans; Male; Membrane Glycoproteins; Mesothelin; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Proteins; Quinolones; Thrombocythemia, Essential | 2003 |